Triple negative breast cancer: looking for the missing link between biology and treatments

Abstract

The so called "Triple Negative Breast Cancer" (TNBC) represents approximately 15-20% of breast cancers. This acronym simply means that the tumour does not express oestrogen receptor (ER) and progesterone receptor (PR) and does not exhibit amplification of the human epidermal growth factor receptor 2 (HER2) gene. Despite this unambiguous definition, TNBCs are an heterogeneous group of tumours with just one common clinical feature: a distinctly aggressive nature with higher rates of relapse and shorter overall survival in the metastatic setting compared with other subtypes of breast cancer. Because of the absence of well-defined molecular targets, cytotoxic chemotherapy is currently the only treatment option for TNBC. In the last decades, the use of more aggressive chemotherapy has produced a clear improvement of the prognosis in women with TNBC, but this approach results in an unacceptable deterioration in the quality of life, also if some support therapies try to relieve patients from distress. In addition, there is the general belief that it is impossible to further improve the prognosis of TNBC patients with chemotherapy alone. In view of that, there is a feverish search for new "clever drugs" able both to rescue chemo-resistant, and to reduce the burden of chemotherapy in chemo-responsive TNBC patients. A major obstacle to identifying actionable targets in TNBC is the vast disease heterogeneity both inter-tumour and intra-tumour and years of study have failed to demonstrate a single unifying alteration that is targetable in TNBC. TNBC is considered the subtype that best benefits from the neoadjuvant model, since the strong correlation between pathological Complete Response and long-term Disease-Free-Survival in these patients. In this review, we discuss the recent discoveries that have furthered our understanding of TNBC, with a focus on the subtyping of TNBC. We also explore the implications of these discoveries for future treatments and highlight the need for a completely different type of clinical trials.

Keywords: biology; breast cancer; oncology; treatments; triple negative.

Figure 1. Principle of neoadjuvant chemotherapy strategy

Figure 2. I-Spy trial

Figure 3. proposed model

α. – Predefined drop of SUV Max and K-Trans + proliferation (Ki67) + predefined increment of apoptosis (caspase). β. – Failure in achieving at least one of the above of the above α criteria; A. – Caelyx + Xel/ Vin or CMF or AR Inhibitor. B. – Maximum Conventional Treatment (platinum-anthracycline-taxane for carriers of BRCA1/2 mutation/BRCA-like genomic instability signature, dose-dense anthracycline-taxane for the other). C. – Different investigational approach according to molecular definition (Example: 1) Carbo-GEM + Parp-Inhibitor for BRACness subtype or Best Standard CT+ AR Inhibitor for LAR subtype)).